Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance.

Bolger GT, Licollari A, Tan A, Greil R, Vcelar B, Majeed M, Helson L.

Anticancer Res. 2017 Jul;37(7):3483-3492.

PMID:
28668837
2.

The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma.

Sordillo PP, Sordillo LA, Helson L.

Anticancer Res. 2017 May;37(5):2159-2171. Review.

PMID:
28476779
3.

In Vitro Study of a Liposomal Curcumin Formulation (Lipocurc™): Toxicity and Biological Activity in Synovial Fibroblasts and Macrophages.

Kloesch B, Gober L, Loebsch S, Vcelar B, Helson L, Steiner G.

In Vivo. 2016 Jul-Aug;30(4):413-9.

PMID:
27381602
4.

Use of basic mobile phase to improve chromatography and boost sensitivity for quantifying tetrahydrocurcumin in human plasma by LC-MS/MS.

Tan A, Wu Y, Wong M, Licollari A, Bolger G, Fanaras JC, Shopp G, Helson L.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 15;1028:86-93. doi: 10.1016/j.jchromb.2016.06.010. Epub 2016 Jun 7.

PMID:
27327398
5.

Curcumin-ER Prolonged Subcutaneous Delivery for the Treatment of Non-Small Cell Lung Cancer.

Ranjan AP, Mukerjee A, Gdowski A, Helson L, Bouchard A, Majeed M, Vishwanatha JK.

J Biomed Nanotechnol. 2016 Apr;12(4):679-88.

PMID:
27301194
6.

Bifunctional role of pro-inflammatory cytokines after traumatic brain injury.

Sordillo PP, Sordillo LA, Helson L.

Brain Inj. 2016;30(9):1043-53. doi: 10.3109/02699052.2016.1163618. Epub 2016 Jun 3. Review.

PMID:
27261102
7.

Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response.

Sordillo LA, Sordillo PP, Helson L.

Anticancer Res. 2016 May;36(5):2085-95. Review.

PMID:
27127108
8.

Curcumin for the Treatment of Glioblastoma.

Sordillo LA, Sordillo PP, Helson L.

Anticancer Res. 2015 Dec;35(12):6373-8. Review.

PMID:
26637846
9.
10.

Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells.

Sordillo PP, Helson L.

Anticancer Res. 2015 Feb;35(2):599-614. Review.

PMID:
25667437
12.

Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans.

Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Bolger G, Helson L, Wolzt M.

Int J Clin Pharmacol Ther. 2015 Jan;53(1):54-65. doi: 10.5414/CP202076.

PMID:
25500488
13.

Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation.

Shopp GM, Helson L, Bouchard A, Salvail D, Majeed M.

Anticancer Res. 2014 Sep;34(9):4733-40.

PMID:
25202051
14.

Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.

Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK.

J Nanobiotechnology. 2013 Dec 14;11:40. doi: 10.1186/1477-3155-11-40.

15.

Effect of liposomal curcumin on red blood cells in vitro.

Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Helson L, Wolzt M.

Anticancer Res. 2013 Sep;33(9):3629-34.

PMID:
24023289
16.

Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis.

Ranjan AP, Mukerjee A, Helson L, Gupta R, Vishwanatha JK.

Anticancer Res. 2013 Sep;33(9):3603-9.

PMID:
24023285
17.

Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats.

Zou P, Helson L, Maitra A, Stern ST, McNeil SE.

Mol Pharm. 2013 May 6;10(5):1977-87. doi: 10.1021/mp4000019. Epub 2013 Apr 22.

18.

Curcumin (diferuloylmethane) delivery methods: a review.

Helson L.

Biofactors. 2013 Jan-Feb;39(1):21-6. doi: 10.1002/biof.1080. Epub 2013 Jan 11. Review.

PMID:
23315886
19.

Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs.

Helson L, Bolger G, Majeed M, Vcelar B, Pucaj K, Matabudul D.

Anticancer Res. 2012 Oct;32(10):4365-70.

PMID:
23060560
20.

Tissue distribution of (Lipocurc™) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs.

Matabudul D, Pucaj K, Bolger G, Vcelar B, Majeed M, Helson L.

Anticancer Res. 2012 Oct;32(10):4359-64.

PMID:
23060559
21.

Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy.

Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK.

J Nanobiotechnology. 2012 Aug 31;10:38. doi: 10.1186/1477-3155-10-38.

22.

Differential distribution of intravenous curcumin formulations in the rat brain.

Chiu SS, Lui E, Majeed M, Vishwanatha JK, Ranjan AP, Maitra A, Pramanik D, Smith JA, Helson L.

Anticancer Res. 2011 Mar;31(3):907-11.

23.

Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.

von Bueren AO, Shalaby T, Rajtarova J, Stearns D, Eberhart CG, Helson L, Arcaro A, Grotzer MA.

BMC Cancer. 2007 Jan 25;7:19.

24.

Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide "scorpion" molecule.

Safavy A, Raisch KP, Matusiak D, Bhatnagar S, Helson L.

Bioconjug Chem. 2006 May-Jun;17(3):565-70.

PMID:
16704191
25.

Multiple myeloma regression mediated by bruceantin.

Cuendet M, Christov K, Lantvit DD, Deng Y, Hedayat S, Helson L, McChesney JD, Pezzuto JM.

Clin Cancer Res. 2004 Feb 1;10(3):1170-9.

26.

Hemangioendothelioma: successful therapy with interferon-alpha: a study in Association with the Italian Pediatric Haematology/Oncology Society (AIEOP).

Deb G, Donfrancesco A, Ilari I, De Sio L, Milano GM, Ghitti C, Fontana G, Sandri A, Helson L.

Med Pediatr Oncol. 2002 Feb;38(2):118-9. No abstract available.

PMID:
11813178
27.

Shortened time to recovery from chemotherapy induced neutropenia in pediatric patients with high dose combined cytokines.

Deb G, Donfrancesco A, Sio LD, Cozza R, Castellano A, Paole F, Helson L.

Anticancer Res. 1998 Jan-Feb;18(1B):489-92.

PMID:
9568167
28.

Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials.

Ahmed T, Lake DE, Beer M, Feldman EJ, Preti RA, Seiter K, Helson L, Mittelman A, Kancherla R, Ascensao J, Akhtar T, Cook P, Goldberg R, Coleman M.

Bone Marrow Transplant. 1997 Mar;19(5):449-54.

29.

Sporadic acute lymphocytic leukemia arising in a patient with neurofibromatosis and xanthogranulomatosis.

Deb G, Habetswallner D, Helson L, De Sio L, Caniglia M, Donfrancesco A.

Cancer Invest. 1996;14(2):109-11.

PMID:
8597895
30.

Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease.

Ahmed T, Lake D, Feldman E, Seiter K, Helson L, Mittelman A, Puccio C, Chun H, Grima K, Akhtar T, et al.

Ann N Y Acad Sci. 1995 Dec 29;770:305-14. No abstract available.

PMID:
8597368
31.

D-CECaT as preoperative chemotherapy for unresectable neuroblastoma in children over one year of age.

Donfrancesco A, Deb G, Dominici C, De Sio L, Inserra A, Boglino C, Takahashi M, Uchino J, Helson L.

Anticancer Res. 1995 Sep-Oct;15(5B):2347-50.

PMID:
8572650
32.

Hemin toxicity in a human epithelioid sarcoma cell line.

Braverman S, Helson C, Helson L.

Anticancer Res. 1995 Sep-Oct;15(5B):1963-7.

PMID:
8572585
33.

Camptothecin cytotoxic effects in vitro: dependency on exposure duration and dose.

Helson L, Helson C, Ainsworth S.

Anticancer Drugs. 1995 Aug;6(4):612-4.

PMID:
7579568
34.

Va-es-bj - an epithelioid sarcoma cell-line.

Helson C, Melamed M, Braverman S, Traganos F, Preti R, Helson L.

Int J Oncol. 1995 Jul;7(1):51-6.

PMID:
21552805
35.

Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group.

Donfrancesco A, De Bernardi B, Carli M, Mancini A, Nigro M, De Sio L, Casale F, Bagnulo S, Helson L, Deb G.

Eur J Cancer. 1995;31A(4):612-5.

PMID:
7576980
37.

Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas.

Ahmed T, Cook P, Feldman E, Coombe N, Puccio C, Mittelman A, Chun H, Coleman M, Helson L.

Leukemia. 1994 Apr;8(4):531-4.

PMID:
8152247
38.

Incidence and treatment of tumor lysis syndrome in patients with acute leukemia.

Razis E, Arlin ZA, Ahmed T, Feldman EJ, Puccio C, Cook P, Chun HG, Helson L, Mittelman A.

Acta Haematol. 1994;91(4):171-4.

PMID:
7976113
39.

delta-Aminolevulinic acid effects on neuronal and glial tumor cell lines.

Helson L, Braverman S, Mangiardi J.

Neurochem Res. 1993 Dec;18(12):1255-8.

PMID:
8272191
40.

Peripheral blood stem cells in children with solid tumors. Part II. Immunocytologic detection of tumor cells in bone marrow and peripheral blood stem cell harvests.

Dominici C, Deb G, Angioni A, Landolfo A, Parisi F, Helson L, Donfrancesco A.

Anticancer Res. 1993 Nov-Dec;13(6B):2573-5.

PMID:
8135496
41.

Peripheral blood stem cells in children with solid tumors. Part I. Feasibility and application.

Deb G, Dominici C, Angioni A, Balloni P, Catena G, Fidani P, De Sio L, Landolfo A, Amici A, Helson L, et al.

Anticancer Res. 1993 Nov-Dec;13(6B):2569-71.

PMID:
7907851
42.

Cerebral ventricular fluid distribution of subcutaneous granulocyte-macrophage colony stimulating factor.

Helson L, Braverman S, Rifkinson S, Helson C.

Anticancer Res. 1993 Sep-Oct;13(5C):1851-5.

PMID:
8267392
43.

Propantheline prevention of mucositis from etoposide.

Ahmed T, Engelking C, Szalyga J, Helson L, Coombe N, Cook P, Corbi D, Puccio C, Chun H, Mittelman A.

Bone Marrow Transplant. 1993 Aug;12(2):131-2.

PMID:
8401358
44.

A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells.

Helson L, Helson C, Malik S, Ainsworth S, Mangiardi J.

Anticancer Drugs. 1993 Aug;4(4):487-90.

PMID:
8104544
45.

D-CECaT: a breakthrough for patients with neuroblastoma.

Donfrancesco A, Deb G, Angioni A, Maurizio C, Cozza R, Jenkner A, Landolfo A, Boglino C, Helson L.

Anticancer Drugs. 1993 Jun;4(3):317-21.

PMID:
8395258
46.
47.

Sequential addition of deferoxamine and hemin inhibits glioma tumor-cell growth.

Braverman S, Helson C, Abraham N, Helson L.

Int J Oncol. 1993 Jan;2(1):97-103.

PMID:
21573522
48.

Total control of chemotherapy induced emesis.

Helson L.

Anticancer Res. 1992 Nov-Dec;12(6B):2243-4.

PMID:
1295471
49.

Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma.

Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, Fidani P, Amici A, Helson L.

Am J Clin Oncol. 1992 Aug;15(4):319-22.

PMID:
1514528
50.

Desferrioxamine in acute iron poisoning.

Helson L, Helson C, Braverman S, Deb G, Donfrancesco A.

Lancet. 1992 Jun 27;339(8809):1602-3. No abstract available.

PMID:
1351568

Supplemental Content

Loading ...
Support Center